Success Metrics

Clinical Success Rate
33.3%

Based on 1 completed trials

Completion Rate
33%(1/3)
Active Trials
6(38%)
Results Posted
200%(2 trials)
Terminated
2(13%)

Phase Distribution

Ph phase_3
3
19%
Ph not_applicable
5
31%
Ph phase_4
1
6%
Ph phase_2
6
38%

Phase Distribution

0

Early Stage

6

Mid Stage

4

Late Stage

Phase Distribution15 total trials
Phase 2Efficacy & side effects
6(40.0%)
Phase 3Large-scale testing
3(20.0%)
Phase 4Post-market surveillance
1(6.7%)
N/ANon-phased studies
5(33.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

33.3%

1 of 3 finished

Non-Completion Rate

66.7%

2 ended early

Currently Active

6

trials recruiting

Total Trials

16

all time

Status Distribution
Active(7)
Completed(1)
Terminated(2)
Other(6)

Detailed Status

unknown6
Recruiting5
Terminated2
Completed1
Not yet recruiting1
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
16
Active
6
Success Rate
33.3%
Most Advanced
Phase 4

Trials by Phase

Phase 26 (40.0%)
Phase 33 (20.0%)
Phase 41 (6.7%)
N/A5 (33.3%)

Trials by Status

completed16%
recruiting531%
terminated213%
not_yet_recruiting16%
unknown638%
active_not_recruiting16%

Recent Activity

6 active trials
Showing 5 of 16
not_yet_recruitingphase_2

HAIC + DEB-TACE + Toripalimab + Lenvatinib for Unresectable Intrahepatic Cholangiocarcinoma

NCT07685535
active_not_recruitingphase_2

Durvalumab and Tremelimumab in Combination With Y-90 SIRT for Intermediate Stage HCC

NCT04522544
recruitingphase_3

DEB-TACE vs cTACE in HCC After TIPS

NCT07322848
recruitingphase_2

ICIs and Anti-VEGF Antibody/TKIs With or Without Interventional Therapy for Advanced HCC

NCT07157969
recruitingphase_2

DEB-TACE+RALOX-HAIC vs DEB-TACE for Large HCC

NCT06397235
View all 16 trials

Clinical Trials (16)

Showing 16 of 16 trials
NCT07685535Phase 2

HAIC + DEB-TACE + Toripalimab + Lenvatinib for Unresectable Intrahepatic Cholangiocarcinoma

Not Yet Recruiting
NCT04522544Phase 2

Durvalumab and Tremelimumab in Combination With Y-90 SIRT for Intermediate Stage HCC

Active Not Recruiting
NCT07322848Phase 3

DEB-TACE vs cTACE in HCC After TIPS

Recruiting
NCT07157969Phase 2

ICIs and Anti-VEGF Antibody/TKIs With or Without Interventional Therapy for Advanced HCC

Recruiting
NCT06397235Phase 2

DEB-TACE+RALOX-HAIC vs DEB-TACE for Large HCC

Recruiting
NCT06353126Phase 4

DEB-TACE Prior to Liver Transplantation in the Treatment of HCC

Recruiting
NCT06192784Phase 2

Combined DEB-TACE, Lenvatinib and Pucotenlimab as Conversion Therapy for Unresectable Intrahepatic Cholangiocarcinoma

Unknown
NCT05103007Not Applicable

PVE/PVL Combined With DEB-TACE in the Treatment of Patients With Large and Unresectable Liver Cancer

Unknown
NCT05788835Not Applicable

DEB-TACE Versus DEB-TACE Sequential HAIC for Unresectable BCLC Stage C HCC; A Randomized Controlled Trial

Recruiting
NCT04174781Phase 2

Anti-PD-1 Antibody Plus DEB-TACE for BCLC Stage A/B HCC

Unknown
NCT02670122

Prospective Study to Evaluate Safety of Deb-TACE With 100µ Beads in Patients With Non Resectable HCC

Completed
NCT04803019Phase 3

Transarterial Embolization Alone Versus Drug-Eluting Beads Chemoembolization for Hepatocellular Carcinoma

Unknown
NCT02460991Phase 3

A Study of ONCO-DOX in Locally Advanced Hepatocellular Carcinoma

Terminated
NCT04738188Not Applicable

Efficacy and Safety of TACE on Downstaging Hepatocellular Carcinoma Beyond UCSF Criteria;

Unknown
NCT03969576Not Applicable

Drug-eluting Bead Transarterial Chemoembolisation (DEB-TACE) Versus (VS) Conventional Transarterial Chemoembolisation (cTACE) for Unresectable Hepatocellualr Carcinoma (HCC)

Unknown
NCT02748161Not Applicable

DEB-TACE for Hepatocellular Carcinoma

Terminated

All 16 trials loaded

Drug Details

Intervention Type
DEVICE
Total Trials
16